<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834405</url>
  </required_header>
  <id_info>
    <org_study_id>B026504</org_study_id>
    <nct_id>NCT00834405</nct_id>
  </id_info>
  <brief_title>Leflunomide 20 mg Tablets, Non-Fasting</brief_title>
  <official_title>A Relative Bioavailability, Parallel Study of Leflunomide 20 mg Tablets Under Non-Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the relative bioavailability of leflunomide 20 mg&#xD;
      tablets (manufactured by TEVA Pharmaceutical Industries, Ltd. and distributed by TEVA&#xD;
      Pharmaceuticals USA) with that of ARAVA 20 mg tablets (Aventis) in healthy, adult,&#xD;
      non-smoking subjects [females (who are unable to become pregnant) and vasectomized males]&#xD;
      under non-fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">May 2002</completion_date>
  <primary_completion_date type="Actual">May 2002</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - Maximum Observed Concentration - Metabolite A77 1726 in Plasma</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours Post-dose (Per Participant) - Metabolite A77 1726</measure>
    <time_frame>Blood samples collected over 72 hour period</time_frame>
    <description>Bioequivalence based on AUC0-72</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Leflunomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leflunomide 20 mg Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arava®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arava® 20 mg Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARAVA® 20 mg tablets</intervention_name>
    <description>1 x 20 mg, single-dose non-fasting</description>
    <arm_group_label>Arava®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leflunomide 20 mg Tablets</intervention_name>
    <description>1 x 20 mg, single-dose non-fasting</description>
    <arm_group_label>Leflunomide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects selected for this study will be non-smokers at least 18 years of age.&#xD;
             Females must be physically unable to become pregnant. Males must be vasectomized.&#xD;
             Weight of the subjects shall not be more than 20% ± from normal for height and body&#xD;
             frame (Metropolitan Life, 1993, Height, Weight, Body Chart).&#xD;
&#xD;
          -  Each subject shall be given a general physical examination within 21 days of&#xD;
             initiation of the study. Such examination includes, but is not limited to, blood&#xD;
             pressure, general observations, and history.&#xD;
&#xD;
          -  Each female subject will be given a serum pregnancy test as part of the pre-study&#xD;
             screening process.&#xD;
&#xD;
          -  Adequate blood and urine samples should be obtained within 21 days before beginning of&#xD;
             the first period and at th eend of the trial for clinical laboratory measurements.&#xD;
&#xD;
          -  Clinical laboratory measurements will include the following:&#xD;
&#xD;
               1. Hematology: hematocrit, hemoglobin, red blood cell count, platelets, white blood&#xD;
                  cell count (with differential).&#xD;
&#xD;
               2. Clinical chemistry: creatinine, BUN, glucose, SGOT/AST, SGPT/ALT, bilirubin, and&#xD;
                  alkaline phosphatase.&#xD;
&#xD;
               3. Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin,&#xD;
                  occult blood, and cells.&#xD;
&#xD;
               4. HIV Screen: pre-study only.&#xD;
&#xD;
               5. Hepatitis-B, C Screen: pre-study only.&#xD;
&#xD;
               6. Drugs of Abuse Screen: pre-study and at check-in before dosing.&#xD;
&#xD;
          -  Subjects will be selected if all above are normal.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a history of chronic alcohol consumption (during past 2 years), drug&#xD;
             addiction, or recent serious gastrointestinal, renal, hepatic or cardiovascular&#xD;
             disease, tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be&#xD;
             eligible for this study.&#xD;
&#xD;
          -  Subjects whose clinical laboratory test values are greater than 20% outside the normal&#xD;
             range may be retested. if the clinical values are outside the range on retesting, the&#xD;
             subject will not be eligible to participate in the study unless the clinical&#xD;
             investigator deems the result to not be significant.&#xD;
&#xD;
          -  Subjects who have a history of allergic responses to the class of drug being tested&#xD;
             should be excluded from the study. Subjects who have a history of allergic responses&#xD;
             to cholestyramine should be excluded from the study.&#xD;
&#xD;
          -  All subjects will have urine samples assayed for the presence of drugs of abuse as&#xD;
             part of the clinical laboratory screening procedures and at check-in before dosing.&#xD;
             Subjects found to have urine concentrations of any of the tested drugs will not be&#xD;
             allowed to participate.&#xD;
&#xD;
          -  Subjects should not have donated blood and/or plasma for at least 30 days prior to the&#xD;
             first dosing of the study.&#xD;
&#xD;
          -  Subjects who have taken any investigational drug within 30 days prior to the first&#xD;
             dosing of the study will not be allowed to participate.&#xD;
&#xD;
          -  Female subjects who are pregnant or who are able (women with child bearing potential)&#xD;
             to become pregnant during the study will not be allowed to participate.&#xD;
&#xD;
          -  All female subjects will be screened for pregnancy at check-in. Subjects with positive&#xD;
             or inconclusive results will be withdrawn from the study.&#xD;
&#xD;
          -  Male subjects who are physically able to father a child will not be allowed to&#xD;
             participate. Male subjects must be vasectomized (at least 3 months) with medical&#xD;
             verification.&#xD;
&#xD;
          -  Subjects who smoke or use tobacco in any form will not be eligible to participate in&#xD;
             the study. Three months abstinence is required.&#xD;
&#xD;
          -  Subjects who are unable to tolerate multiple venipuncture will be excluded.&#xD;
&#xD;
          -  Subjects who have taken any product containing leflunomide within 180 days of dosing&#xD;
             will not be allowed to participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David B. Erasmus, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gateway Medical Research, Inc.</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bioassay Laboratory, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>January 30, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <results_first_submitted>July 2, 2009</results_first_submitted>
  <results_first_submitted_qc>July 2, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>September 9, 2009</last_update_submitted>
  <last_update_submitted_qc>September 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leflunomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Leflunomide</title>
          <description>Leflunomide 20 mg Tablet</description>
        </group>
        <group group_id="P2">
          <title>Arava®</title>
          <description>Arava® 20 mg Tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leflunomide</title>
          <description>Leflunomide 20 mg Tablet</description>
        </group>
        <group group_id="B2">
          <title>Arava®</title>
          <description>Arava® 20 mg Tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax - Maximum Observed Concentration - Metabolite A77 1726 in Plasma</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Leflunomide</title>
            <description>Leflunomide 20 mg Tablet</description>
          </group>
          <group group_id="O2">
            <title>Arava®</title>
            <description>Arava® 20 mg Tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Maximum Observed Concentration - Metabolite A77 1726 in Plasma</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2488.000" spread="385.181"/>
                    <measurement group_id="O2" value="2345.294" spread="266.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-72 and Cmax.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>106</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>98.0</ci_lower_limit>
            <ci_upper_limit>114</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours Post-dose (Per Participant) - Metabolite A77 1726</title>
        <description>Bioequivalence based on AUC0-72</description>
        <time_frame>Blood samples collected over 72 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Leflunomide</title>
            <description>Leflunomide 20 mg Tablet</description>
          </group>
          <group group_id="O2">
            <title>Arava®</title>
            <description>Arava® 20 mg Tablet</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-72 - Area Under the Concentration-time Curve From Time Zero to 72 Hours Post-dose (Per Participant) - Metabolite A77 1726</title>
          <description>Bioequivalence based on AUC0-72</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132584.730" spread="18639.707"/>
                    <measurement group_id="O2" value="123335.784" spread="13732.783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Analysis of variance (ANOVA) was performed on pharmacokinetic parameters of AUC0-72 and Cmax.</non_inferiority_desc>
            <param_type>Geometric Test/Ref Ratio x 100</param_type>
            <param_value>107</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>100</ci_lower_limit>
            <ci_upper_limit>115</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80-125.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

